Leiden, the Netherlands, February 7, 2025: On December 15, 2024, Pharming Technologies B.V. (“Pharming”), a wholly-owned subsidiary of Pharming Group N.V., announced a recommended cash offer to the ...
The multinational Phase III study is evaluating a new pediatric granulated formulation of leniolisib in children aged 1 to 6 years with APDS, a rare primary immunodeficiency Leiden, The Netherlands, ...
Leiden, the Netherlands, June 24, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces it will host a webcast for investors and analysts featuring ...
CSL Behring and Pharming have mutually agreed that CSL will dismiss Pharming from the case against Dr. Chiao Pharming's dismissal did not involve any fault, liability, or penalties against Pharming ...
Fintel on MSN
Pharming Group NV - Depositary receipt (PHAR) price target increased by 11.55% to 19.77
The average one-year price target for Pharming Group N.V. - Depositary Receipt (NasdaqGM:PHAR) has been revised to $19.77 / share. This is an increase of 11.55% from the prior estimate of $17.73 dated ...
This press release is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa or in any other jurisdiction where such offer pursuant to ...
Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Pharming (NASDAQ:PHAR) in the last three months. The following table provides a quick overview ...
Leiden, The Netherlands, October 13, 2008. Biotech companyPharmingGroup NV ("Pharming" or "The Company") (Euronext: PHARM)announcedtoday the appointment of Dr Sijmen de Vries as ChiefExecutiveOfficer ...
LEIDEN, The Netherlands, June 1, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that it has entered into a definitive ...
LEIDEN, NETHERLANDS--(Marketwire - February 22, 2011) - Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) and San Diego based specialty biopharmaceutical company Santarus, Inc.
First came phishing scams, in which con artists hooked unwary internet users one by one into compromising their personal data. Now the latest cyberswindle, pharming, threatens to reel in entire ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results